- Home
- PEN vs DVA Comparison
PEN vs DVA Comparison
Compare PEN & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- DVA
- Stock Information
- Founded
- PEN 2004
- DVA 1994
- Country
- PEN United States
- DVA United States
- Employees
- PEN N/A
- DVA N/A
- Industry
- PEN Medical/Dental Instruments
- DVA Misc Health and Biotechnology Services
- Sector
- PEN Health Care
- DVA Health Care
- Exchange
- PEN Nasdaq
- DVA Nasdaq
- Market Cap
- PEN 9.0B
- DVA 9.7B
- IPO Year
- PEN 2015
- DVA 1995
- Fundamental
- Price
- PEN $265.05
- DVA $140.35
- Analyst Decision
- PEN Strong Buy
- DVA Hold
- Analyst Count
- PEN 16
- DVA 2
- Target Price
- PEN $300.47
- DVA $162.00
- AVG Volume (30 Days)
- PEN 495.8K
- DVA 864.5K
- Earning Date
- PEN 07-29-2025
- DVA 08-05-2025
- Dividend Yield
- PEN N/A
- DVA N/A
- EPS Growth
- PEN 916.05
- DVA 8.72
- EPS
- PEN 3.74
- DVA 10.20
- Revenue
- PEN $1,280,152,000.00
- DVA $13,161,328,000.00
- Revenue This Year
- PEN $14.60
- DVA $6.51
- Revenue Next Year
- PEN $14.24
- DVA $3.41
- P/E Ratio
- PEN $70.81
- DVA $13.77
- Revenue Growth
- PEN 12.92
- DVA 5.09
- 52 Week Low
- PEN $184.80
- DVA $126.07
- 52 Week High
- PEN $310.00
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- PEN 65.25
- DVA 55.30
- Support Level
- PEN $251.29
- DVA $133.12
- Resistance Level
- PEN $260.22
- DVA $135.58
- Average True Range (ATR)
- PEN 7.16
- DVA 3.67
- MACD
- PEN 2.00
- DVA 0.78
- Stochastic Oscillator
- PEN 89.33
- DVA 90.96
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.